Clinical Rheumatology

, Volume 28, Issue 6, pp 673–678

Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus

  • Adel A. Shabana
  • Atef E. El-Ghawet
  • Shereen A. Machaly
  • Ekbal M. Abu Hashim
  • Basma A. El-Kady
  • Reham Shaat
Original Article
  • 106 Downloads

Abstract

There has been a renewed interest in anti-chromatin and anti-histone antibodies in the last few years. To assess the prevalence of anti-chromatin and anti-histone antibodies in patients with systematic lupus erythematosus (SLE) and to correlate serum levels of these antibodies with clinical features of the disease, the presence of anti-chromatin and anti-histone antibodies in 38 patients with SLE was investigated by an enzyme-linked immunosorbent assay (ELISA). To determine the specificity of these antibodies, 15 patients with rheumatoid arthritis, 15 patients with systemic sclerosis, and 15 normal controls were also tested. Sensitivity of anti-chromatin antibodies in SLE patients was 89.5% and specificity was 80.0%, while sensitivity of anti-histone antibodies was 92.1% and specificity was 82.2%. Significant associations were found between the levels of anti-chromatin antibodies and arthritis, malar rash, oral ulcer, pulmonary affection (P < 0.05) also, lupus nephritis (P < 0.01), and disease activity score as measured by SLE disease activity index (SLEDAI; P < 0.001). Significant association was found between anti-histone antibodies and fatigue (P < 0.05). The incidence of positive anti-chromatin and anti-histone antibodies was significantly higher than that of anti-dsDNA antibodies in early stage of the disease. We conclude that anti-chromatin and anti-histone antibodies are both sensitive and specific for SLE and could be a useful addition to the laboratory tests that can help in the diagnosis of SLE. Anti-chromatin antibodies seem to be a promising marker useful in early diagnosis and assessment of disease activity in SLE patients especially in patients who are negative for anti-dsDNA antibodies.

Keywords

Anti-chromatin antibodies Anti-histone antibodies SLE 

Supplementary material

10067_2009_1130_MOESM1_ESM.DOC.doc
Table (1) Suppl.:Prevalence of SLE Clinical manifestation in various populations. (DOC 173 kb)

References

  1. 1.
    Sherer Y, Gorstein A, Frizler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537PubMedCrossRefGoogle Scholar
  2. 2.
    Pisetsky DS (2000) Anti-DNA and autoantibodies. Curr Opin Rheumatol 12:364–368PubMedCrossRefGoogle Scholar
  3. 3.
    Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J (2004) Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 43:220–224PubMedCrossRefGoogle Scholar
  4. 4.
    Tan EM, Cohen AS, Fries JF (1982) The 1982 revised criteria for classification of SLE. Arthritis Rheum 25:377–382Google Scholar
  5. 5.
    Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association (1987): revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatism 31:315–324PubMedCrossRefGoogle Scholar
  6. 6.
    Masi AT, Rodnan GP, Medsger TA et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  7. 7.
    Bombardier C, Gladman DA, Urowitz MB, Caron D, Chang DH (1992) And the committee on prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMedCrossRefGoogle Scholar
  8. 8.
    Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250PubMedCrossRefGoogle Scholar
  9. 9.
    Burlingame RW, Boey ML, Starkebaum G (1994) The central role of chromatin in the autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 94:784–192CrossRefGoogle Scholar
  10. 10.
    Gockel S, Binder WL (1985) Immunoglobulin class specific of antihistone. Arthritis Rheum (supple) 28:558Google Scholar
  11. 11.
    Cervera R, Vinas O, Ramos-Casals M et al (2003) Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 62:431–434PubMedCrossRefGoogle Scholar
  12. 12.
    Gladman DD, Urowitz MB (1997) Systemic lupus erythematosus clinical and laboratory features. In: Klippel JH, Weyond CM, Wortmann RL (eds) Primer on Rheumatic Diseases, 11th edition 250-257Google Scholar
  13. 13.
    Kim WU, Kim SI, Yoo WH, Par JH, Min JK, Kim SC, Hong YS, Lee SH, Cho CS, Kim HY (1999) ARDS in SLE patients: Rheumatic Dis. In: Kang-Nam St Mary’s Hospital p. 552-7Google Scholar
  14. 14.
    Cairns AP, McMillan SA, Crockard AD et al (2003) Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 62:272–273PubMedCrossRefGoogle Scholar
  15. 15.
    Moder KG, Miller TD, Tazelaer HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275PubMedCrossRefGoogle Scholar
  16. 16.
    Roldan CA, Shively BK, Crawford MH (1996) An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 335:1424–1430PubMedCrossRefGoogle Scholar
  17. 17.
    Medina F, Ayala A, Jara LJ, Becerra M, Miranda JM, Fraga A (1997) Acute abdomen is systemic lupus eythematosus: the importance of early laparotomy. Am J Med 103:100–105PubMedCrossRefGoogle Scholar
  18. 18.
    Czaja A, Homburger H (2001) Antibodies in liver disease. Gastroenterology 129:239CrossRefGoogle Scholar
  19. 19.
    Cohen MG, Pollard M, Webb J (1992) Antibodies to histones in systemic lupus erythematosus: prevalence, specificity, and relationship to clinical and laboratory features. Ann Rheum Dis 51:61–66PubMedCrossRefGoogle Scholar
  20. 20.
    Moss KE, Loannou Y, Sutton SM, Hag I, Isenberg DA (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61:409–413PubMedCrossRefGoogle Scholar
  21. 21.
    Haddouk S, Ben M, Baklouti S, Hachicha J, Bahloul Z, Masmoudi H (2005) Clinical significance of antinucleosome antibodies in Tunisian systemic lupus erythematosus patients. Clin Rheumatol 24:219–222PubMedCrossRefGoogle Scholar
  22. 22.
    Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S (1995) Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 38(10):1485–1491PubMedCrossRefGoogle Scholar
  23. 23.
    Sato S, Kodera M, Hasegawa M, Fujimoto M, Takehara K (2004) Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 151:1182–1188PubMedCrossRefGoogle Scholar
  24. 24.
    Quattrocchi P, Barrile A, Bonanno D et al (2005) The role of antinucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases. Reumatismo 57:109–113PubMedGoogle Scholar
  25. 25.
    Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA (2001) An analysis of clinical disease activity and nephritis associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology 40:1405–1412PubMedCrossRefGoogle Scholar
  26. 26.
    Burlingame RW, Cervera R (2002) Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmu Rev 1:321–328CrossRefGoogle Scholar
  27. 27.
    Schett G, Smolen J, Zimmermann C et al (2002) The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 11:704–715PubMedCrossRefGoogle Scholar
  28. 28.
    Ghedira I, Landolsi H, Mankai A, Fabien N, Jeddi M (2006) Antihistones antibodies in systemic lupus erythematosus, comparison of three assays: ELISA, dot blot and immunoblot. Pathol Biol (Paris) 54:148–154Google Scholar
  29. 29.
    Amoura Z, Koutouzov S, Chabre H et al (2000) Presence of anti-nucleosome autoantibodies in a restricted set of connective tissue diseases. Arthritis Rheum 43:76–84PubMedCrossRefGoogle Scholar
  30. 30.
    Sato S, Ihr H, Kikuchi K, Takehara K (1994) Antih-histone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391–394PubMedCrossRefGoogle Scholar
  31. 31.
    Hasegawa M, Sato S, Kikuchi K, Takehara K (1998) Antigen specificity of anti-histone antibodies in systemic sclerosis. Ann Rheum Dis 57:470–475PubMedCrossRefGoogle Scholar
  32. 32.
    Gomez-Puerta JA, Molina JF, Anaya JM, Molina J (2001) Clinical significance anti-chromatin antibodies in systemic lupus erythematosus. Lupus 10(supp1):S73Google Scholar
  33. 33.
    Hmida Y, Schmit P, Gilson G, Humbel RL (2002) Failure to detect antinucleosome antibodies in scleroderma: comment on the article by Amoura et al. Arthritis Rheum 46:280–282PubMedCrossRefGoogle Scholar
  34. 34.
    Ghirardello A, Doria A, Zampieri S et al (2004) Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimm 22:235–240CrossRefGoogle Scholar
  35. 35.
    Gomez-Puerta JA, Burlingame RW, Cervera R (2006) Anti-chromatin (anti-nucleosome) antibodies. Lupus 15:408–411PubMedCrossRefGoogle Scholar
  36. 36.
    Wallace DJ, Lin HC, Shen GQ (1994) Antibodies to histone (H2A–H2B) DNA complexes in the absence of antibodies to double-strand DNA or to (H2A–H2B) complexes are more sensitive and specific for scleroderma–related disorders than for lupus. Arthritis Rheum 37:1795–1797PubMedCrossRefGoogle Scholar
  37. 37.
    Gonzalez C, Garcia-Berrocal B, Herraez O, Navajo AJ, Gonzalez-Buitrago J (2004) Antinucleosome, antichromatin, anti-ds DNA and anti-histone antibody reactivity in systemic lupus erythematsus. Clin Chem Lab Med 42:266–272PubMedCrossRefGoogle Scholar
  38. 38.
    Fritzler M, Salazar M (1991) Diversity and origin of rheumatology autoantibodies. Clin Microbial Rev 4:256–269Google Scholar
  39. 39.
    Gompertz NR, Isenberg DA, Turner BM (1990) Correlation between clinical features of systemic lupus erythematosus and levels of antihistone antibodies of the IgG, IgA and IgM isotypes. Ann Rheum Dis 49:524–527PubMedCrossRefGoogle Scholar
  40. 40.
    Min DJ, Kim SJ, Park SH et al (2002) Anti-nucleosome antibody: significance in lupus patients lacking anti-double stranded DNA antibody. Clin Exp Rheum 20:13–18Google Scholar
  41. 41.
    Siegert CE, Daha M, Westedt ML (1991) IgG autoantibodies against CIq are correlated with nephritis, hypocomplementaemia, and ds DNA antibodies in systemic lupus disease. J Rheumatol 18:230–234PubMedGoogle Scholar
  42. 42.
    Siegert CE, Daha MR, Tseng CM (1993) Predictive value of IgG autoantibodies against CIq for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:851–856PubMedCrossRefGoogle Scholar
  43. 43.
    Cortés-Hernández J, Ordi-Ros J, Labrador M (2004) Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methyl prednisolone. Lupus 12:287–298CrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Adel A. Shabana
    • 1
  • Atef E. El-Ghawet
    • 1
  • Shereen A. Machaly
    • 1
  • Ekbal M. Abu Hashim
    • 2
  • Basma A. El-Kady
    • 1
  • Reham Shaat
    • 1
  1. 1.Rheumatology and Rehabilitation department, Mansoura Faculty of MedicineMansoura UniversityMansouraEgypt
  2. 2.Clinical Pathology Department, Mansoura, Faculty of MedicineMansoura UniversityMansouraEgypt

Personalised recommendations